Neurocrine Biosciences Inc vs Johnson & Johnson
NBIX vs JNJ — side-by-side comparison from reported financials. NBIX leads 4, JNJ leads 5 of 9 comparable metrics.
Neurocrine Biosciences Inc
NBIX · Healthcare
$142.44+0.84%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | NBIX | JNJ |
|---|---|---|
| Price | $142.44 | $261.79 |
| Market cap | $14.5B | $631B |
| Revenue (TTM) | $3.37B | $97.9B |
| Revenue growth | +24.3% | +5.6% |
| Net margin | 20.9% | 21.5% |
| Free cash flow | $866M | $22.2B |
| Net cash (debt) | $1.01B | ($27.8B) |
| 1-year price return | +2.9% | +37.0% |
| P/E | 20.5 | 29.9 |
| P/E vs own history (cheap-side %) | 90% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 21% | 26% |
| Altman Z-score | 6.23 | — |
| CV checks passed | 10 of 10 | 10 of 10 |
| Employees | 2,500 | 140,800 |
Full résumé-style profiles: NBIX CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.